COMMUNIQUÉS West-GlobeNewswire

SciSparc Updates Regarding the Status of the AutoMax Merger
14/08/2024
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its shareholders to approve [...]
Yield10 Bioscience Announces Second Quarter 2024 Financial Results
14/08/2024
WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended [...]
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
14/08/2024
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
14/08/2024
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release [...]
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
14/08/2024
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results [...]
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
14/08/2024
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today [...]
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
14/08/2024
Company to host conference call on August 15, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]
PetVivo Reports Reports Fiscal Q1 2025 Results
14/08/2024
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering [...]
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
14/08/2024
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer [...]
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
14/08/2024
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) program Early indication of monotherapy activity in [...]
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14/08/2024
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management [...]
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
14/08/2024
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14/08/2024
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and [...]
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
14/08/2024
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
14/08/2024
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 [...]
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
14/08/2024
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 [...]
Seer Appoints Nicolas Roelofs to its Board of Directors
14/08/2024
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas [...]
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
14/08/2024
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened [...]
STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
14/08/2024
HORSHAM, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Pages